A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients

• DOI: 10.1097/cji.0b013e3181f4c208
• Publication Date: 2010-10-13T11:49:58Z
• Authors: Olivier Adotevi; Helene Pere; Patrice Ravel; Nacilla Haicheur; Cecile Badoual; Nathalie Merillon; Jacques Medioni; Severine Peyrard; Stephane Roncelin; Virginie Verkarre; Arnaud Mejean; Wolf H. Fridman; Stephane Oudard; Eric Tartour
• Keywords: Circulating tumor cell; Immunosuppression

Sunitinib, an antiangiogenic molecule, is one of the first-line standard care in treatment patients with metastatic renal cell carcinoma. However, it only benefits to a subgroup and no predictive markers sunitinib efficacy have been identified. Twenty-eight carcinomas were treated sunitinib-based therapy another 7 primary cancer also by neoadjuvant trial. Measurements CD3+CD4+CD25hi Foxp3+ regulatory T cells, immunosuppressive population, performed before after each cycle blood tumor prospective study. We observed decrease number peripheral cells therapy. The overall survival was significantly longer showing 2 or 3 cycles (P<0.05). positively correlated their at baseline (P<0.01), but not modification volume defined Response Evaluation Criteria Solid Tumors criteria. clinical relevance these results supported intratumoral 5 out Our study represents first work reporting that measurement may value on response. Antiangiogenic reversed immunosuppression microenvironment which provides novel argument human favor its combination immunotherapy.